Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain immune cells (called microglia) become overactive. A heart failure medication called sacubitril-valsartan has been shown to reduce the risk of developing dementia, but it is not known whether this is because it reduces brain inflammation. This study uses a new experimental brain scan drug called [11C]PS13 (PS13) to measure brain inflammation directly and non-invasively, using a technique called positron emission tomography (PET). PS13 sticks to a molecule called COX-1, which is found mainly in brain immune cells (microglia). By measuring how much PS13 accumulates in the brain, researchers can estimate how much brain inflammation is present. In this pilot study, 18 patients with heart failure and mild memory or thinking problems who are being started on sacubitril-valsartan by their cardiologist (as standard clinical care) will undergo two brain PET scans: one before starting sacubitril-valsartan, and one approximately 12 weeks after. The study will also assess memory, thinking, daily function, mood, and social well-being using standard questionnaires. The study will test whether sacubitril-valsartan is associated with measurable changes in brain inflammation, and whether this type of imaging is feasible in heart failure patients. The study is funded by the American Heart Association and the National Institute on Aging, and an independent Data and Safety Monitoring Board oversees participant safety. The results will be used to design a larger study.

Start Date01 Oct 2026

Sponsor / Collaborator

Stony Brook University

[+2]

NCT07853625

/ Not yet recruitingNot ApplicableIIT

Comparative Efficacy of Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive Patients: A Randomized Controlled Trial

Hypertension is a leading global risk factor for cardiovascular disease and is frequently associated with left atrial and ventricular remodeling, leading to subclinical diastolic dysfunction[cite: 2]. Left Atrial Volume Index (LAVI) serves as a sensitive indicator of left ventricular diastolic dysfunction and a key predictor of adverse cardiovascular outcomes, including atrial fibrillation, stroke, and heart failure with preserved ejection fraction (HFpEF)[cite: 2]. Reversing or preventing left atrial enlargement is critical to improving long-term prognosis in hypertensive patients[cite: 2].
While sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor, ARNI) has demonstrated significant clinical benefits in heart failure, limited data exist regarding its comparative efficacy against valsartan alone in reversing left atrial remodeling in hypertensive patients with preserved ejection fraction (LVEF >50%)[cite: 2].
This randomized controlled trial aims to evaluate and compare the efficacy of sacubitril/valsartan versus valsartan monotherapy in reducing LAVI and improving blood pressure control over a 6-month treatment period in hypertensive patients with preserved ejection fraction and enlarged left atrium (LAVI >34 mL/m²)[cite: 2].

Start Date01 Oct 2026

Sponsor / Collaborator

University of Health Sciences Lahore

TCTR20260808008

/ Not yet recruitingPhase 1

A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 97 mg/103 mg Tablets in Healthy Thai Subjects under Fasting Conditions

Start Date06 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Sacubitril/Valsartan

100 Translational Medicine associated with Sacubitril/Valsartan

100 Patents (Medical) associated with Sacubitril/Valsartan

699

Literatures (Medical) associated with Sacubitril/Valsartan

31 Dec 2026·mAbs

Efficient brain delivery and sustained retention of antibodies via dual targeting of blood–brain barrier and intra-brain proteins

Article

Author: Haraya, Kenta ; Kato, Atsuhiko ; Kawashima, Masashi ; Okuda, Momoko ; Sato, Kazuki ; Noguchi, Yuki ; Shu, Feng ; Hironiwa, Naoka ; Nagaya, Nishiki ; Kuramochi, Taichi ; Yamazaki, Masaki ; Nakagawa, Keitaro

Efficient delivery of therapeutic antibodies to the brain has been increasingly achieved using receptor-mediated transcytosis (RMT) approaches such as transferrin receptor (TfR)-mediated shuttle systems. Moreover, a strategy for enhancing brain retention has recently emerged as a focus of attention to overcome the rapid clearance of TfR shuttles from the brain. Here, we propose a novel approach that combines binding to intra-brain proteins, such as myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, and chondroitin sulfate proteoglycan 5, for sustained retention in the brain with binding to blood-brain barrier (BBB) proteins, such as TfR and insulin-like growth factor 1 receptor, for enhanced BBB permeability. A mouse pharmacokinetic study demonstrated that the anti-MOG/TfR antibody reached a higher maximum concentration and maintained higher concentrations in the brain for 4 months than anti-MOG and anti-TfR antibodies. In immunohistochemistry and brain 3D-imaging study, the anti-MOG/TfR antibody distributed throughout the whole brain, suggesting it penetrates the BBB across the whole brain parenchyma and is retained there. Finally, this antibody technology was applied to brain delivery of neprilysin, an enzyme that degrades amyloid beta, demonstrating that it can enhance both the brain exposure and the pharmacodynamic effect of the potential therapeutic molecule. In conclusion, the concept of achieving sustained high brain exposure by combining BBB transport with enhanced brain retention was shown to be broadly applicable. This novel antibody technology platform is expected to deliver and retain various therapeutic molecules efficiently within the brain, addressing critical challenges in drug development for the central nervous system.

01 Dec 2026·AMERICAN HEART JOURNAL

Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor–neprilysin inhibition in acute heart failure: Insights from the PREMIER study

Article

Author: Hikoso, Shungo ; Matsue, Yuya ; Nogi, Kazutaka ; Izawa, Hideo ; Tanaka, Atsushi ; Kawai, Hideki ; Doi, Shunichi ; Kamishita, Kohei ; Obokata, Masaru ; Node, Koichi ; Kida, Keisuke ; Imai, Takumi

BACKGROUND:

Sacubitril/valsartan (Sac/Val) reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in acute heart failure (AHF), particularly in patients with reduced ejection fraction. However, whether estimated total blood volume (TBV), calculated using anthropometric equations, is associated with heterogeneity in biomarker response remains uncertain.

METHODS:

This post hoc exploratory sub-analysis of the PREMIER randomized trial evaluated whether baseline estimated TBV was associated with heterogeneity in NT-proBNP reduction after Sac/Val compared with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy. Estimated TBV was calculated using validated anthropometric equations and dichotomized at the median (4.05 L). Patients were further stratified by left ventricular ejection fraction (LVEF <40% vs ≥40%). The primary endpoint was the proportional change in NT-proBNP from baseline to Week 8.

RESULTS:

Among 376 patients, 372 with baseline estimated TBV data were analyzed. In the high TBV group, Sac/Val was associated with greater NT-proBNP reduction than ACEI/ARB (-56% vs -32%; ratio of change, 0.67; 95% confidence interval, 0.53-0.84; P = .001), whereas no significant difference was observed in the low TBV group (P for heterogeneity = 0.063). In patients with LVEF <40%, Sac/Val was associated with greater NT-proBNP reduction in both TBV groups. In patients with LVEF ≥40%, Sac/Val was associated with greater NT-proBNP reduction in the high TBV group, whereas the point estimate in the low TBV group numerically favored ACEI/ARB.

CONCLUSIONS:

In this exploratory post hoc analysis, higher estimated TBV was associated with greater NT-proBNP reduction after Sac/Val, particularly among patients with LVEF ≥40%. These findings are hypothesis-generating and require external validation.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT05164653; Japan Registry of Clinical Trials, jRCTs021210046.

01 Nov 2026·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Lactobacillus casei Zhang modulates hippocampal metabolism and cognition in T2DM rats: a microbiota-gut-brain axis study

Article

Author: Liu, Sijie ; Kang, Yan ; Liu, Huili ; Cheng, Linlin ; Lin, Fuchun ; Wang, Xuxia ; Cai, Yue ; Chen, Xi ; Guo, Haodong

The gut plays a pivotal role in metabolic disorders, providing a tractable target for type 2 diabetes mellitus (T2DM) prevention. Although Lactobacillus casei Zhang (LCZ) demonstrates cognitive benefits in T2DM, the mechanism by which LCZ modulates the gut microbiota to ameliorate cognition decline remains unelucidated. Therefore, we investigated the protective effects of LCZ against diabetic encephalopathy via the microbiota-gut-brain axis. Forty-two male Sprague-Dawley rats were randomly assigned to three groups (n=14/group): saline control (CON), T2DM group, and T2DM prevented with LCZ (T2DM+LCZ). Cognitive function was assessed by novel object recognition and Y-maze tests. Hippocampal metabolism was analyzed via ¹H NMR-based metabolomics. Gut microbiota composition was determined by 16S rRNA sequencing, and fecal short-chain fatty acid (SCFA) levels were quantified using targeted metabolomics. Compared with CON, T2DM rats exhibited significant increases in fasting blood glucose and insulin resistance, cognitive deficits, hippocampal metabolism disruption, elevated hippocampal inflammation, altered gut microbiota composition, and reduced SCFA. LCZ intervention (T2DM+LCZ group) effectively mitigated these T2DM-induced alterations, significantly lowering fasting blood glucose and insulin resistance, improving cognitive function, attenuating hippocampal inflammation, normalizing hippocampal metabolites, and restoring gut microbiota composition and SCFA levels. Crucially, no significant differences in most metrics were observed between the T2DM+LCZ and CON groups. Our findings demonstrate that LCZ alleviates T2DM-induced cognitive impairment by modulating the microbiota-gut-brain axis. Specifically, LCZ administration restores SCFA production and partially remodeled brain metabolism, highlighting its therapeutic promise for preventing diabetic encephalopathy.

332

News (Medical) associated with Sacubitril/Valsartan

13 Oct 2026

·www.biospace.com

Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure

In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF on top of guideline-directed medical therapy, with a favorable safety and tolerability profile Company continues to advance tovinontrine in a pioneering clinical program targeting PDE9 in heart failure Results from the Cycle Phase 2 clinical trials will be presented in a plenary session at Heart Failure Society of America Annual Scientific Meeting Oct. 11, 2026 -- Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced the presentation of data from its Phase 2 Cycle clinical program evaluating tovinontrine (CRD-750) as a novel treatment for heart failure. In patients with heart failure with reduced ejection fraction (HFrEF) in the Cycle-1REF trial, tovinontrine at two of three doses tested achieved reductions in NT-proBNP, a biomarker of heart failure, through 12 weeks of treatment. Patients enrolled in the Phase 2 Cycle clinical program were already receiving robust background guideline-directed medical therapy for heart failure, including high rates of Entresto® and SGLT2 inhibitor use. At all doses tested, tovinontrine demonstrated a favorable safety profile. Tovinontrine is an orally administered phosphodiesterase-9 (PDE9) inhibitor that represents a new mechanism to enhance the natriuretic peptide signaling (NPS) pathway specifically in the cardiomyocyte for the treatment of patients with heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for the treatment of chronic heart failure. Phase 2 results from the Cycle-1REF and Cycle-2PEF clinical trials were presented today in a late-breaking plenary session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, ASM 2026 in Phoenix, Arizona. “We are pleased to share these important Phase 2 results from our Cycle program, showing that tovinontrine achieved substantial reduction in the primary endpoint, NT-proBNP, in patients with HFrEF, demonstrating clinical proof of concept for PDE9 inhibition in heart failure. With these Phase 2 efficacy results and favorable safety profile, Cardurion plans to continue advancing tovinontrine as a potential first-in-class therapy to augment existing guideline directed therapies. Tovinontrine has now demonstrated the potential to offer additional benefit to patients on top of current therapies for heart failure, which remains a leading cause of mortality,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. The Cycle-1REF Phase 2 clinical trial randomized 529 participants at global sites to one of three doses of tovinontrine or placebo, on a background of guideline-directed medical therapy. Reductions in NT-proBNP from baseline at 12 weeks were greatest at the tovinontrine 2.5 mg BID dose and slightly smaller reductions were seen at the 25 mg BID dose, with decreases in NT-proBNP observed as early as week 2 and sustained through the 12-week treatment period. Reductions in BNP and increases in plasma and urinary cGMP, both supportive of pathway engagement and biological activity, were observed alongside the NT-proBNP effect. No benefit in NT-proBNP levels was observed at the highest dose (50 mg BID) of tovinontrine tested in the clinical trial. Reductions in NT-proBNP were consistent among patients on and off background Entresto® and other therapies, supporting the use of tovinontrine with existing guideline-directed regimens. Dr. Surks continued, “Our scientific team has worked closely with our scientific advisors and Cycle investigators to understand the inverse dose-response observed with tovinontrine in heart failure patients, as we pioneer the development of PDE9 inhibition in heart failure. We believe that this inverse dose-response reflects a counter-regulatory neurohormonal feedback mechanism, triggered by the very high levels of intracellular cGMP achieved in the myocardium at maximal PDE9 inhibition. This hypothesis is supported by published studies and further analysis of the Cycle data which showed an effect where plasma cGMP elevations beyond a threshold attenuated beneficial downstream signaling by the natriuretic receptor signaling pathway.” “I am highly encouraged by the Cycle study results that position tovinontrine as a promising new therapeutic option to treat heart failure. Reductions in NT-proBNP achieved at the two lower doses of tovinontrine in HFrEF patients, and particularly the reductions of NT-proBNP seen with lower levels of cGMP elevations, suggest a compelling path forward in the clinic,” said Dr. James Udelson, Chief of the Division of Cardiology at Tufts Medical Center and Principal Investigator for the Cycle clinical trials. “Furthermore, it is gratifying to be part of a clinical effort with Cardurion that is advancing our understanding of a central mechanism in heart failure, so that we can establish a stronger foundation for developing new therapies for millions of patients.” In addition, results from the Cycle-2PEF Phase 2 trial were presented in a late-breaking presentation at HFSA ASM 2026. In the Cycle-2 PEF trial, 277 patients with heart failure with preserved ejection fraction (HFpEF) were randomized to receive tovinontrine 50 mg BID or placebo. Consistent with the absence of an NT-proBNP effect at the highest dose in Cycle-1REF, no significant change in NT-proBNP was observed in Cycle-2PEF at this dose. Additional evaluation of tovinontrine at lower doses in the HFpEF population is warranted. In both the Cycle-1REF and Cycle-2PEF clinical trials, tovinontrine demonstrated a favorable safety and tolerability profile. Phosphodiesterase (PDE) 9 is an enzyme whose elevated activity in patients with heart failure reduces the beneficial effects of the natriuretic peptide signaling (NPS) pathway. The NPS pathway plays an important and protective role in cardiac function, and its activation has been shown to confer outcomes benefit for patients with heart failure. PDE9 is significantly upregulated in patients with chronic heart failure, causing disruption in the NPS pathway. Cardurion is the first company to demonstrate clinical proof-of-mechanism for PDE9 inhibition in patients with chronic heart failure with its PDE9 program. Heart failure is a prevalent and growing condition that is responsible for substantial morbidity and mortality. Approximately 6.7 million adults in the United States suffer from heart failure, and approximately 50 percent of these patients die from the condition within five years of diagnosis. One in five patients with heart failure are hospitalized annually, and approximately 25 percent of these patients are re-admitted within a month of discharge. Approximately half of all patients with chronic heart failure have reduced ejection fraction (HFrEF) and half have preserved ejection fraction (HFpEF), categorized as different diseases based on the pumping ability of the heart. Significant unmet medical needs remain in heart failure, despite the reductions in morbidity and mortality from currently approved treatments for heart failure. Cardurion Pharmaceuticals is a clinical-stage biotechnology company discovering and developing new therapeutic approaches to address cardiovascular diseases. Cardurion has extensive expertise in cardiovascular biology, signaling pathways and drug discovery and development, and it translates that expertise into potentially groundbreaking therapeutics with the promise to address the unmet needs of patients. Cardurion’s clinical-stage pipeline consists of product candidates targeting phosphodiesterase-9 (PDE9) and calcium/calmodulin-dependent protein kinase II ( CaMKII). Cardurion is the first company to advance product candidates against these novel and important targets into clinical testing for the treatment of cardiovascular disease. Cardurion is headquartered in Burlington, Massachusetts, with discovery sciences and research facilities in Shonan, Japan. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

11 Sep 2026

·www.biospace.com

Novartis’ board faces investor scrutiny after M&A misfires and R&D flops

iStock, lerbank Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s. Novartis went into September looking forward to three readouts that analysts had identified as central to its mid- to long-term growth prospects. Days later, the Swiss drugmaker was reeling from the failures of two of the pivotal trials, offsetting success in the other study and adding to pressures created by a recent decision to suspend CAR T efforts in response to three patient deaths. Guggenheim Securities analysts set out what was at stake for Novartis ahead of the run of readouts. In an Aug. 17 note to investors, the analysts called readouts on pelacarsen, remibrutinib and del-desiran major clinical catalysts that “will be important for gaining confidence in Novartis’ mid- and long-term sales potential.” The run of key readouts started well, with Novartis reporting that its BTK inhibitor remibrutini—approved last September as Rhapsido for chronic spontaneous urticaria—lowered annualized relapse rates in a pair of Phase 3 multiple sclerosis trials. However, within days of the success, Novartis revealed that its antisense therapy pelacarsen showed no significant benefit on cardiovascular risk and that the antibody-oligonucleotide conjugate del-desiran flunked a muscle-wasting disease study. Cardiovascular disease Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen. September 8, 2026 · 2 min read · Tristan Manalac Read more Novartis acquired del-desiran last year in the $12 billion buyout of Avidity Biosciences. The risk that Novartis will fail to realize a return on the buyout has intensified investor scrutiny of leadership’s M&A strategy. Successive Novartis chairs have failed on acquisitions, and the company must change how it oversees deals, David Samra, managing director at Artisan Partners, told Reuters . Artisan is a major shareholder in Novartis. CEO Vasant Narasimhan has done a “very good job” running Novartis, Samra said, but the board has failed to properly scrutinize deals. Samra named Novartis’ $2.9 billion takeover of MorphoSys in 2024 as another poor deal. Between acquiring a controlling stake in MorphoSys in May and closing the deal in October, Novartis recorded an $800 million impairment related to an assessment of the biotech’s data. Novartis’ patent cliff The M&A misfires and recent back-to-back Phase 3 flops may have long-term consequences. In a July 21 note, Guggenheim analysts called the pelacarsen, remibrutinib and del-desiran readouts “critical” to Novartis’ post-2030 growth. The focus on the post-2030 period reflects the need to replace products that could power sales through the rest of this decade before stuttering in the face of off-patent rivals. U.S. patents on Cosentyx, Kisqali and Kesimpta are scheduled to expire from 2029 to 2031. The products were Novartis’ three best-selling drugs in the first half of 2026, accounting for almost 38% of total sales. Novartis’ fourth best-selling product, Entresto, has already lost exclusivity. Entresto sales halved in the second quarter, but the drug still generated $1.2 billion over that three-month period. Recent setbacks raise questions about Novartis’ preparations for the 2029 to 2031 patent expirations. The current leadership team has a track record of successfully navigating such challenges, with Novartis’ sales rising this year amid a loss-of-exclusivity period that CFO Mukul Mehta recently called the largest the company has ever faced. Appointed CEO in 2018, Narasimhan equipped Novartis to grow through the expirations now eroding sales through moves like the $2.1 billion takeover of Endocyte, which developed Pluvicto. Sales of the radiopharmaceutical rose 57% to $1.3 billion in the first half of the year, making it Novartis’ fifth best-selling drug. Pluvicto is the only drug in the top five with a patent loss after 2031. Recent developments raise doubts about whether Novartis’ deals for the next set of potential growth drivers will be as successful. Novartis’ agreement to license pelacarsen from Ionis predated Narasimhan’s appointment as CEO, although the drug candidate moved into a Phase 3 cardiovascular outcomes study on the executive’s watch. Pelacarsen’s chances of helping Novartis grow through the 2030s appear to have shrunk to zero. Analysts at BMO Capital Markets, Guggenheim and TD Cowen removed the drug candidate from their models for Novartis and partner Ionis in response to the Phase 3 flop. Novartis’ investor relations team “does not foresee future development” of pelacarsen, Guggenheim analysts said in a Sept. 9 note to investors. Justifying Avidity Novartis “plans to continue exploring del-desiran and potentially conduct further studies to support a path to market,” the Guggenheim analysts said. Even so, the failure of the Phase 3 HARBOR trial led the Guggenheim team to cut risk-adjusted 2033 sales estimate for del-desiran in myotonic dystrophy type 1 from $1.76 billion to $960 million, using a 60% probability of success. Guggenheim analysts said in their Aug. 17 note that “success for del-desiran in HARBOR is crucial for validating the Avidity deal.” Novartis’ investor relations team took a different view, telling the analysts that either del-desiran or del-brax, another antibody-oligonucleotide conjugate from Avidity, could justify the acquisition. Earnings Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table. July 21, 2026 · 2 min read · Tristan Manalac Read more Analysts see del-brax, a potential treatment for facioscapulohumeral muscular dystrophy, having lower peak sales than del-desiran. The analyst estimates Novartis presented at the time of the Avidity deal showed peak sales forecasts of up to $6 billion for del-desiran and $4 billion for del-brax. After the del-desiran flop, Guggenheim analysts cut their 2033 risk-adjusted sales estimate for del-brax from $1.76 billion to $600 million, using a 50% probability of success. Novartis reported Phase 1/2 data on the candidate in June. While Novartis’ base case is that the drug will be ready for an approval filing in 2028, the company plans to talk to the FDA about an earlier submission based on biomarker data, Narasimhan said in July. Novartis acquired a third drug candidate, the Duchenne muscular dystrophy prospect del-zota, in the Avidity buyout, but the asset is unlikely to justify the takeover alone. Guggenheim analysts forecast risk-adjusted del-zota sales of $430 million in 2033 at a 95% probability of success.

Phase 3AcquisitionExecutive ChangeDrug ApprovalOligonucleotide

19 Aug 2026

·www.biospace.com

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio ® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding pro abelacimab in patients with atrial fibrillation, including recurrent bleeding events Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice Basel, August 19, 2026 – Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. “The data we are presenting at this year’s ESC Congress underscore our commitment to advancing cardiovascular science for patients who remain at risk despite current treatment,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. “From foundational medicines Leqvio and Entresto to promising investigational therapies, our portfolio reflects our focus on addressing persistent challenges in cardiovascular care.” Key abstracts accepted by ESC include: Medicine/Disease Abstract Title Presentation Details Leqvio ® Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial Tripoli (Hall B1) Late-Breaking Oral Presentation August 31, 08:15-08:30 CEST Leqvio ® An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial Exchange Circle 3 (Research Gateway – Hall A1) ePoster August 29, 09:15-10:00 CEST Abelacimab Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA-TIMI71 Science Box 2 (Research Gateway – Hall A1) Oral Presentation August 29, 09:30-10:30 CEST Lipoprotein (a) [Lp(a)] Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis Exchange Circle 6 (Research Gateway – Hall A1) ePoster August 29, 16:15-17:00 CEST Entresto ® Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial Station 5 (Research Gateway – Hall A1) ePoster August 31, 09:15-10:00 CEST Pacibekitug TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk Munich (Main Auditorium-Hall B3) Hot Line August 29, 08:45-09:00 CEST About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing the boundaries of what's possible so more people can live longer, healthier lives. Building on our 40-year legacy, we're committed to shaping what's next in cardiovascular care through bold science and a diverse, industry-leading pipeline. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

AHAPhase 3Clinical Result

100 Deals associated with Sacubitril/Valsartan

External Link

KEGG	Wiki	ATC	Drug Bank
D10226	-	C09DX04	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	China	Novartis Pharma Schweiz AG	24 May 2021
Hypertension	Japan	Novartis Pharma KK	29 Jun 2020
Left ventricular systolic dysfunction	United States	Novartis Pharmaceuticals Corp.	01 Oct 2019
Reduced ejection fraction co-occurrent and due to chronic heart failure	European Union	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	Iceland	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	Liechtenstein	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	Norway	Novartis Europharm Ltd.	19 Nov 2015
Heart Failure	Switzerland	Novartis AG	17 Sep 2015
Chronic heart failure	United States	Novartis Pharmaceuticals Corp.	07 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Postmyocardial infarction syndrome	Phase 3	-	Novartis Pharmaceuticals Corp.	26 May 2021
Erectile Dysfunction	Phase 3	Germany	Novartis Pharmaceuticals Canada, Inc.	16 Apr 2019
Heart Failure, Systolic	Phase 3	Germany	Novartis Pharmaceuticals Canada, Inc.	16 Apr 2019
Acute myocardial infarction	Phase 3	United States	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	China	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Australia	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Austria	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Brazil	Novartis Pharmaceuticals Corp.	09 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05164653 (PREMIER, Pubmed \| Am Heart J)	Phase 4	Heart Failure	372	Sacubitril/valsartan	vomcyxipix(gndwmkkjaj) = jennwzpkrp khkmwunngk (dvkjqqnslo )	Positive	01 Dec 2026
				Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB)	vomcyxipix(gndwmkkjaj) = dysphrexdf khkmwunngk (dvkjqqnslo )
NCT04153136 (CTgov)	Phase 2	Heart failure with normal ejection fraction \| Acquired Immunodeficiency Syndrome	39	Sacubitril-Valsartan 49-51Mg Oral Tablet (Sacubitril/Valsartan)	bknewozpmq(mqjkhfeics) = svqvxqfiel ubwiotddqk (xzrwboptli, 0.015) View more	-	09 Oct 2026
				Placebo oral tablet (Placebo)	bknewozpmq(mqjkhfeics) = skzedidlcf ubwiotddqk (xzrwboptli, 0.013) View more
ESC2026	Not Applicable	Heart failure with reduced ejection fraction	698	Sacubitril-valsartan	wfykegwocs(rgkpvnolux) = cedxzmzhei itrgnbqigt (chxtvwljzq )	Positive	30 Aug 2026
PRADA II (ESC2026)	Phase 2	Early Stage Breast Carcinoma	138	Sacubitril/valsartan	rzhjfjetwp(dbyvahlghn): P-Value = 0.57 View more	Negative	29 Aug 2026
				Placebo
ESC2026	Not Applicable	Heart Failure	206	ARNI/SGLT2i	mxtudkykqf(bcvrnqfski) = fzqszjculg pgxbsncacr (zfrccedplu ) View more	Positive	28 Aug 2026
				Neither ARNI nor SGLT2i	mxtudkykqf(bcvrnqfski) = ndlzvkpjpb pgxbsncacr (zfrccedplu ) View more
ESC2026	Not Applicable	Heart failure with reduced ejection fraction	117	Sacubitril/valsartan	qiidkhryvm(lmapfrjrmg) = frqyrljivi uqwkqtwxbl (axuaiiuaqb ) View more	Positive	28 Aug 2026
NCT04113109 (CTgov)	Phase 4	Heart Failure	46	placebo+valsartan+sacubitril (Placebo)	mkylojungs(opyneuflip) = fnrsdjdshg rezyhrynjr (pbyjxkygiz, 9.47) View more	-	11 Aug 2026
				Icatibant (Icatibant)	mkylojungs(opyneuflip) = kbqwezbhhn rezyhrynjr (pbyjxkygiz, 8.37) View more
PREMIER (ESC2026)	Not Applicable	Heart Failure cardio-inflammatory biomarkers	375	Sacubitril/valsartan	izghtgnnxf(cmguychyoo) = gyjfwwonxm enxvmpxevr (zcdmrcdeia, -11 to 9)	Negative	11 May 2026
				ACEI/ARB	aztujsbmdg(tgkwaofrww) = qcasqjirwe xjnwnllrtu (vfrisnzjqo, -11 to 17) View more
NCT04023227 (PARACHUTE-HF, CTgov)	Phase 4	Chagas Cardiomyopathy \| Heart Failure	922	Sacubitril/valsartan (Sacubitril/Valsartan)	tfhlsfkfjn = sndanhjfqm rwnnvbhlhg (olsjyexuxi, yoflqlrwcx - uptkfdeuaw) View more	-	11 May 2026
				enalapril (Enalapril)	tfhlsfkfjn = bhahtgzoim rwnnvbhlhg (olsjyexuxi, pxymmdvydi - hgxtaxifld) View more
ESC2026	Not Applicable	Heart Failure	206	ARNI/SGLT2i	nywskaehfu(obczvvqvpf) = hlxjcatfho oucinzmeog (bsujwasnej ) View more	Positive	10 May 2026
				Neither ARNI nor SGLT2i	nywskaehfu(obczvvqvpf) = wlpweifgyx oucinzmeog (bsujwasnej ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis